We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Actavis Reaches Tentative Deal To Exit Testosterone MDL

Law360 (June 29, 2018, 6:12 PM EDT) -- Actavis Inc. is on its way to settling claims it failed to warn men about risks associated with its drug Androderm as part of multidistrict litigation over testosterone replacement therapy products, according to an order filed Friday.

In the order staying cases in the MDL against Actavis and several related entities, U.S. District Judge Matthew Kennelly said attorneys for both sides told him they have reached a memorandum of understanding on a potential global settlement.

Actavis is only the latest pharmaceutical company to head for the exit in the MDL in recent months. Auxilium Pharmaceuticals LLC, Eli Lilly & Co., Endo...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Attached Documents


Kirkland & Ellis LLP has redefined what it means to be the biggest of BigLaw — weighing in at 2,116 attorneys by year end 2018 and becoming the first firm since Law360 began tracking law firm head counts to top 2,000 U.S.-based attorneys.



Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only


Judicial Panel on Multidistrict Litigation

Nature of Suit


Subscribers Only

Date Filed

March 28, 2014

Law Firms


Judge Analytics